Evidence map›Paper›PMID 9989832›Full record

ArticleOncogene1999

Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.

D H Yan, Y Wen, B Spohn, D Choubey, J U Gutterman, M C Hung

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

D H YanDepartment of Tumor Biology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.
Y Wen
B Spohn
D Choubey
J U Gutterman
M C Hung
The University of Texas MD Anderson Cancer Center · USMolecular Oncology (United States) · US

Funding

NEU ONCOGENE IN BREAST CANCERR01CA058880 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI HUNG, MIEN-CHIE · 1993 to 2004
$915k
INTERFERONS AND CELL GROWTH REGULATIONR29CA069031 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI CHOUBEY, DIVAKER NONE · 1996 to 2000
$117k
NCI NIH HHS CA 58880NCI NIH HHS CA69031
6 · The paper itself

Abstract

Interferons (IFNs) can exert cytostatic and immunomodulatory effects on carcinoma cells. In particular, growth inhibition of human prostate carcinoma by IFNs has been demonstrated both in vitro and in vivo. p202 is a 52 kd nuclear phosphoprotein known to be induced by IFNs. In this report, we showed that the expression of p202 was associated with an anti-proliferative effect on human prostate cancer cells. More importantly, cells that expressed p202 showed reduced ability to grow in soft-agar, indicating a loss of transformation phenotype. Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its expression may also suppress transformation phenotype of prostate cancer cells.

Indexed as

Cell Transformation, NeoplasticIntracellular Signaling Peptides and ProteinsProstatic NeoplasmsCarrier ProteinsCell DivisionGene ExpressionGrowth InhibitorsHumansInterferon-alphaMalePhenotypePhosphoproteinsTumor Cells, CulturedTumor Suppressor p53-Binding Protein 1Carrier ProteinsGrowth InhibitorsInterferon-alphaIntracellular Signaling Peptides and ProteinsPhosphoproteinsTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1

Identifiers

PMID9989832
OpenAlexW2334881962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.